C
ardiovascular disease is the leading cause of death globally, with atherosclerotic lesions leading to myocardial infarction, stroke, and peripheral vascular disease. Although focal lesions can be treated by percutaneous intervention or bypass graft, these procedures can be complicated by intimal hyperplasia. 1 Smooth muscle cells (SMCs) retain a plasticity that allows for wound healing but also contributes to intimal hyperplasia. In response to vessel injury, quiescent, differentiated medial SMCs undergo a phenotypic modulation to a myofibroblast phenotype in which they proliferate and migrate to the vessel lumen, where they secrete extracellular matrix (ECM) and form a neointima. SMC proliferation is an early response to injury, but lesion growth continues over time as a result of SMC deposition of ECM, including collagens and fibronectin. 2 Because this matrix can comprise up to 80% of the lesion volume, 3 understanding the mechanisms underlying SMC ECM synthesis remains an important question.
Transforming growth factor β (TGF-β) is a central regulator of ECM deposition in vascular injury and in injury-induced fibrosis in many tissues. 4 TGF-β precursor is synthesized intracellularly and secreted into the ECM as an inactive latent complex. On binding to activating molecules such as matrix metalloproteinases or αv integrins, this complex undergoes a conformational change or proteolysis to release the active TGF-β dimer that binds to the cell surface receptor TGFβR2 to elicit downstream signaling through canonical and noncanonical pathways. 5 The canonical SMAD2/3 pathway mainly mediates fibrotic responses, as SMAD3 knockout is sufficient to inhibit fibrosis in fibroblast and inflammatory cells. 6 TGF-β stimulates SMAD2 and SMAD3 phosphorylation and nuclear translocation to activate gene transcription in association with SMAD4. 5 TGF-β-mediated ECM synthesis is essential for wound repair, but excess ECM deposition leads to fibrosis. Thus, identifying mechanisms that promote appropriate resolution of TGF-β signaling is critical. We identify the protein LIM (Lin11, Isl-1 & Mec-3) domain only 7 (LMO7) as a novel negative feedback regulator of TGF-β signaling and ECM deposition. LMO7 is a 150-kDa scaffolding protein containing proteinprotein interaction domains including calponin homology, PDZ (PSD95, Dlg1 & ZO-1), F-Box, and LIM domains. 7, 8 LMO7 localizes to plasma membrane, cytoskeleton, and nucleus and has been shown to play roles in adherens junction assembly, 7 cell migration, 9 and gene transcription. 10 Little is known regarding detailed molecular mechanisms or in vivo phenotypes, as adult mice with germline deletion of Lmo7 appear normal, but aged knockout mice develop spontaneous lung adenocarcinoma.
11 LMO7 plays roles in skeletal muscle transcription and in cardiac development, 10, 12 but its role in SMCs has not been investigated. Because LMO7 has been shown to be induced by TGF-β1 in hepatoma cells, 13 we aimed to investigate the function of LMO7 in ECM synthesis and vascular injury response in SMCs downstream of TGF-β.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure from the corresponding author on reasonable request. Additional detailed methods are available in the online-only Data Supplement.
Mice

Lmo7
−/− mice in C57BL/6J background were obtained from Dr Jun Miyoshi (Osaka Medical Center, Japan). 11 Experimental Lmo7 −/− and littermate control mice were generated from heterozygous knockout breeding pairs. Lmo7 fl/fl mice obtained from Dr Ju Chen (University of California San Diego) 14 
Clinical Perspective
What Is New?
• We identify the protein LIM domain only 7 (LMO7) as a transforming growth factor β target gene that provides negative feedback signaling to transforming growth factor β.
• By regulating transcription factors that control expression of transforming growth factor β and its activators, LMO7 contributes to the resolution of the wound healing phase in vascular lesions.
What Are the Clinical Implications?
• LMO7 expression is low in normal vessels but is induced after vascular injury. • LMO7 negative feedback mechanisms limit the proliferative and fibrotic responses that drive intimal hyperplasia after vascular injury.
• LMO7 levels are elevated during hyperplastic vascular remodeling, including in human arteries with cardiac allograft vasculopathy and in veins in maturing arteriovenous fistulae.
• LMO7 may be a new mechanistic target for modulation of fibrotic responses.
was induced by injecting 6-week-old mice with 50 mg/kg tamoxifen for 5 days, followed by 5-day recovery before surgery. Control mice also received tamoxifen. Genotyping was performed by polymerase chain reaction. Mice were housed in pathogen-free conditions in Yale University animal facilities. All experiments were approved by the Yale University Institutional Animal Care and Use Committee. mice were used as control. For carotid artery ligation, 8-to 16-week-old mice were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine. The left common carotid artery was exposed, separated from the vagus nerve, and completely ligated using 6-0 silk suture immediately proximal to the carotid bifurcation. 15 Mice were euthanized at between 3 to 28 days after surgery by cardiac perfusion with PBS+sodium nitroprusside followed by 4% paraformaldehyde. The injured and contralateral uninjured arteries were dissected, fixed, dehydrated, and embedded in optimal cutting temperature compound (Tissue Tek, Elkhart, IN) for cryosectioning. The femoral artery wire denudation model was performed and analyzed as described 16 on 20-g mice using a 0.010" guide wire (Modern Grinding, Port Washington, WI).
Animal Experiments
Human Tissue Samples
Deidentified matured patent human arteriovenous fistula (AVF) samples were provided by Yale Vascular Surgery. Samples were obtained after ≥6 months of hemodialysis during surgical revision of the fistula resulting from severe anastomotic stenosis. The samples analyzed are of a segment of normally remodeling patent vein from the fistulae. Control veins were obtained from renal disease patients at time of initial AVF creation. 
Statistical Analysis
Values are presented as mean±SEM. Statistical analysis was performed using Prism 7 (GraphPad). Comparisons between 2 samples were performed using a nonparametric Mann-Whitney U test. Data sets with independent groups were analyzed by 1-way ANOVA followed by the Sidak multiple comparisons test. Experiments comparing 2 independent variables were analyzed by 2-way ANOVA with additive interaction model followed by Holm-Sidak multiple comparisons testing. Comparisons between 2 curves were performed by nonlinear regression with extra sum-ofsquares F test. Tests are 2-sided. P values <0.05 were considered significant.
RESULTS
Loss of LMO7 in SMC Exacerbates Intimal Hyperplasia and ECM Deposition
SMCs contribute to vascular remodeling through phenotypic switching, proliferation, and ECM deposition. Because the function of LMO7 is unknown in SMCs, we initially assessed its expression in response to vascular injury. Wild-type (WT) mice were subjected to carotid artery ligation to induce intimal hyperplasia. 15 Immunostaining showed that LMO7 was expressed at modest levels in uninjured vessels and was highly induced from day 7 postinjury, peaking at day 10 but remaining elevated through 28 days ( Figure 1A) . Notably, the initial induction of LMO7 followed the initiation of TGF-β signaling as indicated by SMAD3 phosphorylation (p-SMAD3) staining ( Figure 1A ). Because TGF-β1 is induced over time in response to vascular injury and contributes to intimal hyperplasia through SMC proliferation and ECM synthesis, 17 we next determined whether LMO7 is a TGF-β1 target gene in SMC. LMO7 mRNA ( Figure IA in the online-only Data Supplement) and protein ( Figure IB and IC in the online-only Data Supplement) were induced by TGF-β1 treatment in human coronary artery SMC (CASMC) in a concentrationand time-dependent manner, with peak protein expression at 0.5 ng/mL TGF-β1 up to 48 hours.
To study the function of LMO7 in vascular injury, mice with germline deletion of Lmo7 (Lmo7 −/− ) 11 were subjected to carotid artery ligation or femoral artery denudation. 18 Elastic Van Gieson staining revealed that whereas the contralateral uninjured vessels showed no significant morphological difference between Lmo7 
Lmo7
iΔSM medial and intimal layers versus control. Increased ECM deposition was also observed in germline knockout mice with both vascular injury models ( Figure  IVB through IVE in the online-only Data Supplement). Consistent with these in vivo findings, expression of major ECM genes Col1a1, Col1a2, Col3a1, and Fn1 was higher in aortic SMCs cultured from Lmo7 −/− mice, with up to 10-fold more than in WT SMC ( Figure 1G ). As expected, TGF-β1 treatment induced expression of 
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ECM genes in WT and Lmo7 −/− cells; however, the total levels of ECM genes after TGF-β1 treatment were much greater in Lmo7 −/− cells, reaching up to 25-fold over the WT baseline levels ( Figure 1G ). The medial layer of freshly isolated mouse aorta (uninjured mice) also demonstrated a modest induction of ECM gene mRNAs in Lmo7 −/− mice ( Figure IVF in the online-only Data Supplement). Although both proliferation and ECM deposition contribute to neointimal expansion and are interrelated, we sought to assess the relative contribution of these processes to the LMO7 loss-of-function phenotype. For carotid ligation injury, there was a nominally greater increase in neointimal size (3.76±3.10-fold) relative to the increase in neointimal cell number (2.16±1.15-fold) in . These data collectively suggest that LMO7 is induced by TGF-β1 in SMCs and that LMO7 deficiency leads to hyperproliferation and enhanced ECM deposition, which both contribute to exaggerated neointimal formation following vascular injury.
TGF-β Signaling and ECM Gene Expression Are Augmented in LMO7-Deficient SMCs
Given that injured LMO7-deficient vessels display exaggerated intimal hyperplasia and ECM deposition, and that LMO7 is itself a TGF-β1 target gene, we predicted that LMO7 induction may serve as a negative feedback regulator of TGF-β signaling that functions to limit the injury response. To test this hypothesis, we assessed p-SMAD3 as an indicator of TGF-β activity postinjury. p-SMAD3 immunostaining was stronger in the neointima of Lmo7 iΔSM vessels than in controls at 28 days postinjury, and was mainly nuclear (Figure 2A ), indicating increased TGF-β activity. ACTA2 levels were elevated at 28 days postinjury in the Lmo7 iΔSM mouse, also consistent with elevated TGF-β signaling (Figure 2A ). Immunostaining for TGF-β 19 or its effector connective tissue growth factor (CTGF) also revealed enhanced TGF-β activity in Lmo7 iΔSM vessels 28 days postinjury ( Figure 2B ). Enhanced TGF-β signaling was also observed in injured femoral arteries from Lmo7 iΔSM mice and Lmo7 −/− mice (Figure VI in the online-only Data Supplement). Importantly, we noted an increase in TGF-β or CTGF at all time points assessed from 3 to 28 days after carotid ligation injury in Lmo7 iΔSM compared with control mice. Whereas CTGF peaked at day 14 and then declined in control mice, there was no such decline in Lmo7 iΔSM mice ( Figure 2C ), indicating that loss of LMO7 induced an increased and more persistent TGF-β signal. Consistent with these findings, TGF-β1 induced higher levels of p-SMAD3 in Lmo7 −/− mouse SMCs, which was significant at 0.5 ng/mL TGF-β1, the dose used throughout this study ( Figure 2D ).
To determine whether enhanced TGF-β signaling is responsible for the increased neointima and ECM deposition in Lmo7 −/− mice, we blocked this signaling by injecting mice daily postinjury with the TGFβ-R1 inhibitor SB431542. Inhibition of TGF-β signaling was confirmed by reduced p-SMAD3 staining ( Figure 
Loss of LMO7 Induced Elevated Expression of TGF-β1 and αvβ3 Integrin, a Latent TGF-β1 Activator
To understand how loss of LMO7 augments TGF-β effects, we examined the expression of Tgfb1 mRNA and activating proteins in control and LMO7-deficient mice. Tgfb1 mRNA levels were higher in Lmo7 −/− mice than controls in normal, uninjured aorta ( Figure 3A) .
Lmo7
−/− SMC also expressed higher Tgfb1 mRNA levels than the controls at baseline ( Figure 3B ). TGF-β1 is known to transcriptionally induce its own expression in a form of positive feedback regulation, 20 and this autoinduction resulted in greater maximal level of Tgfb1 in Lmo7 −/− SMC compared with control (Figure 3B ). These increases in mRNA were reflected in the secreted protein levels, as a 2-fold induction of total TGF-β1 secretion was detected in the conditioned medium from Lmo7 −/− SMCs versus controls ( Figure 3C ). Addition of TGF-β neutralizing antibodies to the media reduced the elevated ECM gene expression in Lmo7 −/− cells to the level of the WT baseline ( Figure 3D ). A, Quantitative polymerase chain reaction (qPCR) analysis of Tgfb1 gene expression in medial layers of freshly isolated mouse aortas (n=4 independent experiments). B, Mouse smooth muscle cells (SMCs) were treated with 0.5 ng/mL TGF-β1 for 24 hours, and mRNA was harvested for qPCR analysis of Tgfb1 gene (n=4 independent experiments). Two-way ANOVA revealed a significant effect of LMO7 depletion and TGF-β1 treatment on Tgfb1 mRNA expression, but there was no significant interaction between Lmo7 −/− and TGF-β1 treatment. C, Lmo7 +/+ or Lmo7 −/− mouse SMCs with the same confluency were cultured in 0.5% fetal bovine serum for 24 hours. Conditioned media was harvested to quantitate total TGF-β secretion by ELISA. (n=4 independent experiments) . D, qPCR analysis of extracellular matrix (ECM) genes from Lmo7 +/+ or Lmo7 −/− mouse SMCs treated with 40 μg/mL TGF-β neutralizing antibody (Clone No. 1D11) or vehicle for 24 hours (n=3 independent experiments). Two-way ANOVA revealed a significant effect of LMO7 depletion and anti-TGF-β neutralizing antibody treatment on mRNA expression. LMO7 depletion resulted in a greater magnitude of reduction by neutralizing antibody treatment for Col1a1 mRNA (P=0.0022). E, Immunostaining of ACTA2 (red), β3 integrin (green), and αv integrin (white) on tissue sections from control and Lmo7 iΔSM mice 21 days after femoral artery injury. Scale bar, 50 μm. Cells from each mouse were randomly picked, and β3 and αv integrin staining intensity was measured and normalized to cell area. Quantification is shown on right (n=4). (Continued )
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A recent study by Henderson et al 21 revealed αv integrins as a key regulator of activation of latent TGF-β and tissue fibrosis in multiple organs. In addition to promoting its own transcription, TGF-β can promote its own activation through transcriptional induction of integrin subunits. 22 Expression of αvβ3 integrin, the most abundant αv integrin in blood vessels, is induced by vascular injury, 23 and its inhibition using peptidomimetics dramatically attenuates restenosis. 24 Notably −/− mouse SMCs expressed higher baseline levels of αv and β3 mRNA than controls ( Figure 3F ). TGF-β1 treatment induced αv and β3 mRNA in control cells, and levels were greatly increased in Lmo7 −/− aortic smooth muscle cells ( Figure 3F ). To assess the role of αvβ3 integrin in the Lmo7 −/− phenotype, we treated the mouse aortic smooth muscle cells with cilengitide, a specific αvβ3 integrin inhibitor. 25 Western and quantitative polymerase chain reaction analysis showed that cilengitide inhibited the increased SMAD3 phosphorylation ( Figure 3G ) and the enhanced expression of ECM genes ( Figure 3H ) in Lmo7 −/− SMCs. Cilengitide also inhibited the increased expression of Tgfb1 mRNA in Lmo7 −/− SMCs ( Figure 3H ). These data indicate that enhanced αvβ3 expression in Lmo7 −/− SMCs, likely through activation of latent TGF-β, contributes to upregulation of TGF-β itself, downstream SMAD3 signaling, and increased ECM target gene expression.
LMO7 Inhibits Activator Protein 1 Activity and TGF-β1 Autoinduction
Our data suggest that LMO7 represses TGF-β signaling by reducing expression and integrin-mediated activation of TGF-β. We next sought to investigate the molecular mechanism by which LMO7 regulates TGF-β1 and αvβ3 integrin expression. TGF-β1 autoinduction is mediated by the transcription factor activator protein 1 (AP-1), 26 a heterodimer comprising subunits of the JUN, FOS, and ATF families. TGF-β1 can induce the expression of AP-1. 27 AP-1 contributes to tumorigenesis, 28 SMC proliferation 29 and, interestingly, TGF-β1 26 and β3 integrin 30 gene transcription. Because TGF-β1 and AP-1 form a positive feedback loop to enhance TGF-β1 signaling, we determined whether LMO7 regulates AP-1 activity. Quantitative polymerase chain reaction analysis showed a significantly higher mRNA level of the AP-1 subunits Jun and Fos in the medial layer of Lmo7 −/− mouse aorta relative to controls ( Figure 4A ). Expression of Jun and Fos was also elevated in Lmo7 −/− mouse SMCs compared with WT, and treatment with TGF-β1 further induced their expression in both control cells and Lmo7 −/− SMCs ( Figure 4B ). Human CASMCs with LMO7 small interfering RNA knockdown exhibited an increased expression of c-JUN and c-FOS protein, as well as elevated p-SMAD3 and β3 integrin expression ( Figure 4C ). Both the TGFB1 and ITGB3 genes contain AP-1-binding sites (TRE elements) in their proximal promoter regions implicated in enhanced expression of these genes. 26, 30 Increased AP-1 binding to these elements was detected in human CASMC after LMO7 knockdown in chromatin immunoprecipitationquantitative polymerase chain reaction assays using antibodies to endogenous c-JUN or c-FOS ( Figure IX in the online-only Data Supplement, Figure 4D ).
To determine whether AP-1 plays a causal role in the enhanced TGF-β signaling in Lmo7 −/− SMC, we used the small molecule T5224, a specific inhibitor of c-FOS/AP-1 that targets the basic region/leucine zipper domain. 31 Notably, T5224 was reported to effectively inhibit TGF-β-induced collagen expression and tissue fibrosis in scleroderma. 32 Similarly, in vivo administration of T5224 significantly inhibited the enhanced ECM deposition (Figure 4E ) and neointimal formation ( Figure XA and XB in the online-only Data Supplement) in Lmo7 −/− mice compared with vehicle-treated controls after carotid ligation surgery. This was accompanied by reduced p-SMAD3 staining in the injured Lmo7 −/− carotid artery ( Figure 4F ). Cell culture experiments confirmed that the enhanced SMAD3 phosphorylation in Lmo7 −/− SMCs was also inhibited by T5224 treatment ( Figure 4G) . Furthermore, the upregulation of genes in Lmo7 −/− relative to control SMCs, including Tgfb1, Itgav, and Itgb3, was reduced to the WT baseline or lower by T5224 treatment (Figure 4H) . As AP-1 factors also undergo transcriptional autoinduction, 33 we similarly noted AP-1-dependent regulation of Fos and Jun in Lmo7 −/− cells ( Figure 4H ). TGF-β1 secretion by Lmo7 −/− SMCs was also inhibited by T5224 ( Figure 4I ). Because AP-1 can positively regulate SMC proliferation, 29 the enhanced proliferation of Lmo7 −/− cells may also be attributable to the induced AP-1 expression. Indeed, T5224 reduced Ki67 staining in injured Lmo7 −/− artery ( Figure XC and XD in the online-only Data Figure 3 Continued. F, Mouse SMCs were treated with 0.5 ng/mL TGF-β1 for 24 hours, and mRNA was harvested for qPCR analysis of Itgav and Itgb3 genes (n=3 independent experiments). Two-way ANOVA revealed a significant effect of LMO7 depletion and TGF-β1 treatment on mRNA expression, but there was no significant interaction between Lmo7 −/− and TGF-β1 treatment. G and H, Mouse SMCs were treated with 20 μmol/L cilengitide or vehicle for 24 hours, and cell lysates were harvested for (G) Western analysis of SMAD3 phosphorylation (n=3 independent experiments) or (H) qPCR analysis of ECM and Tgfb1 genes (n=3 independent experiments). Hprt1 was used as a negative control in qPCR analysis. Two-way ANOVA revealed a significant effect of LMO7 depletion and cilengitide treatment on SMAD3 phosphorylation and mRNA expression, and the magnitude of reduction was greater with cilengitide treatment in Lmo7 (n=4 independent experiments) . B, Mouse smooth muscle cells (SMCs) were treated with 0.5 ng/mL TGF-β1 for 24 hours, and mRNA was harvested for qPCR analysis of Jun and Fos genes (n=5 independent experiments). Two-way ANOVA revealed a significant effect of LMO7 depletion and TGF-β1 treatment on mRNA expression, but there was no significant interaction between Lmo7 −/− and TGF-β1 treatment. C, Western analysis of human coronary artery SMCs (CASMCs) transfected with control or LMO7 siRNA for 72 hours. Quantification of c-JUN and c-FOS is shown on right (n=4 independent experiments). D, Chromatin immunoprecipitation (ChIP) with c-JUN or c-FOS antibodies from human CASMCs transfected with control or LMO7 siRNA for 72 hours, followed by qPCR analysis using primers flanking the AP-1 binding sites in TGFB1 or ITGB3 promoters (n=4 independent experiments). E and F, Lmo7 +/+ or Lmo7 −/− mice were subjected to carotid ligation and injected intratracheally with T5224 (30 mg/kg per day) or vehicle (polyvinylpyrrolidone solution) daily from day 4 postligation. Mice were euthanized at day 14, and carotid arteries were harvested. Trichrome (E) or p-SMAD3 (F) staining of cross-sections of injured arteries is shown. p-SMAD3 staining intensity per cell area was measured and is shown on the right (n=4). Two-way ANOVA revealed a significant effect of LMO7 depletion and T5224 treatment on p-SMAD3 staining intensity, and the magnitude of reduction by T5224 treatment was greater in 
LMO7 Suppresses c-FOS and c-JUN by Mediating Their Ubiquitination and Proteasomal Degradation
Because c-FOS and c-JUN proteins are tightly regulated by the proteasomal degradation pathway, 35, 36 we determined whether LMO7 regulates AP-1 protein stability. The short half-lives of AP-1 proteins were greatly extended from ≈15 minutes for c-FOS and ≈45 minutes for c-JUN to 60 and 90 minutes, respectively, in Lmo7 −/− SMCs ( Figure 5A ). LMO7 contains multiple protein-protein interaction domains, including an F-Box motif. 8 Because F-Box motifs can recruit substrates to a Skp-Cullin-F-Box E3 ligase complex for degradation, it is possible that LMO7 may regulate AP-1 subunit stability via this motif. We determined that LMO7 coimmunoprecipitated with c-JUN and c-FOS in human CASMCs ( Figure 5B) . Whereas a modest difference in immunoprecipitated c-FOS or c-JUN was observed between control and LMO7 small interfering RNA-transfected human CASMC at baseline, treatment with the 26S proteasome inhibitor MG132 revealed a pronounced ubiquitin laddering pattern in these immunoprecipitates in control but not LMO7 small interfering RNAtransfected cells ( Figure 5C ), suggesting that LMO7 
Hprt1 was used as a negative control in qPCR analysis. Two-way ANOVA revealed a significant effect of LMO7 depletion and T5224 treatment on p-SMAD3 phosphorylation and mRNA expression, and the magnitude of reduction by T5224 treatment was greater in Lmo7 −/− SMCs for Itgb3 (P=0.026) and Fos (P=0.019) mRNA only. I, Lmo7 +/+ or Lmo7 −/− mouse SMCs with the same confluency were treated with 40 μmol/L T5224 or vehicle for 24 hours. Conditioned media was harvested to quantitate total TGF-β secretion by ELISA (n=3 independent experiments). Two-way ANOVA revealed a significant effect of LMO7 depletion and T5224 treatment on TGF-β1 production, but there was no significant interaction between Lmo7 −/− and T5224 treatment. Data are expressed as mean±SEM. AP-1 indicates activator protein 1; and siRNA, small interfering RNA. *P<0.05, **P<0.01, ***P<0.001.
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Because LIM domains are known for scaffolding activity, we tested the hypothesis that the LIM domain mediates interaction between LMO7 and AP-1 components. We mutated the mouse Lmo7 cDNA, deleting the C terminus, which encodes the LIM domain (LMO7ΔC). Intriguingly, full-length LMO7, but not LMO7ΔC, coimmunoprecipitated with c-FOS or c-JUN in HEK293A cells ( Figure 6A) . Functionally, full-length LMO7 but not the ΔC mutant inhibited the expression of Jun, Fos, Tgfb1 as well as integrin and ECM gene mRNAs ( Figure 6B) . Similarly, overexpression of full-length LMO7 in Lmo7 −/− SMC inhibited c-FOS, c-JUN, and integrin β3 protein expression and SMAD3 phosphorylation, whereas LMO7ΔC failed to do so ( Figure 6C ). These data collectively suggest that the C-terminal LIM domain region of LMO7 is required for interaction with and degradation of c-FOS and c-JUN. LMO7 loss of function leads to an upregulation of AP-1 expression and DNA binding, resulting in upregulation of the TGF-β pathway and its targets (see model, Figure 7 ).
LMO7 Expression Is Inversely Correlated With p-SMAD3 in Human Intimal Hyperplasia
To determine whether the role for LMO7 observed in murine vascular injury models translates to human vascular disease, we assessed levels of LMO7 and p-SMAD3 staining in human samples of coronary arteries from patients with cardiac allograft vasculopathy ( Figure 8A ) and veins from patients with AVF ( Figure 8B ), both of which are characterized by neointimal hyperplasia associated 
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with elevated TGF-β. 37, 38 Preliminary analysis of small numbers of rare human samples suggested that LMO7 levels were low in normal control vessels but increased in the disease samples. Furthermore, when quantitated on a per-cell basis, an inverse correlation between expression of LMO7 and p-SMAD3 was detected in the neointimal regions in the cardiac allograft vasculopathy patient samples (Figure 8) , with a trend toward this relationship in the AVF samples, consistent with our findings in murine injury-induced intimal hyperplasia.
DISCUSSION
The molecular mechanisms that distinguish between normal wound healing and progression to fibrosis are poorly understood but of major importance for many diseases. We identify a key role for the LIM domain protein LMO7 in limiting fibrosis. We report that LMO7 is induced by TGF-β1 and serves as a negative feedback regulator of the TGF-β signaling pathway. By diminishing TGF-β expression, activation, signaling, and target gene expression, our kinetic data suggest that LMO7 contributes to the resolution phase of intravascular wound healing. LMO7 exerts this broad influence on the pathway by regulating the stability of the AP-1 transcription factor subunits c-FOS and c-JUN (Figure 7) . ECM remodeling is a major component of the tissue repair process. Excessive ECM deposition, however, leads to fibrosis or scarring, altering stiffness and impairing tissue function. Thus, appropriate resolution of wound healing is critical. TGF-β plays a central role in stimulating ECM production, 4 and TGF-β propagates wound healing through its own AP-1-dependent autoinduction. 26 Because LMO7 itself is induced by TGF-β, but only after a delay and at higher concentrations, it serves as a sensor of the level of TGF-β signaling. When TGF-β signaling is of sufficient strength and duration to induce LMO7, LMO7 mediates negative feedback that limits ECM production. By regulating TGF-β signaling at multiple levels within the pathway, including transcription of TGF-β as well as its activator αvβ3, LMO7 can coordinately limit TGF-β bioavailability, downregulating expression of TGF-β target genes. Although we have noted regulation of canonical TGF-β signaling mediators including p-SMAD3 and CTGF, it remains to be determined whether LMO7-dependent feedback also influences noncanonical TGF-β signaling.
Mechanistically, we find that LMO7 suppresses TGF-β autoinduction and integrin transcription by regulating AP-1 protein stability. AP-1 regulates many key genes and processes involved in ECM remodeling and wound healing, including proliferation, 29 TGF-β, 26 collagen, 39 and matrix metalloproteinases. 40 Previous studies demonstrated an induction of c-JUN and c-FOS expression in fibrosis in mice and in scleroderma patient dermal fibroblasts, and AP-1 inhibition abrogated TGF-β signaling, myofibroblast phenotype, and ECM deposition in fibroblasts. 32 The short-lived AP-1 subunits c-FOS and c-JUN are tightly regulated 35, 36 by E3 ligases 41, 42 as well as a proteasome-independent pathway. 43 We find that LMO7, through its LIM domain, is able to associate with c-FOS and c-JUN and facilitate their ubiquitination and proteasomal degradation, likely via the LMO7 FBox motif. 8 Through attenuation of AP-1 activity, LMO7 coordinately reduces TGF-β signaling. Importantly, we report that AP-1 inhibition rescues the Lmo7 −/− phenotype in vitro and in vivo.
LMO7 has previously been implicated in skeletal muscle transcriptional regulation and in heart development. 10, 12 Although its functions in smooth muscle had not been previously studied, LMO7 has been linked to cancer cell migration downstream of MKL-1 (MRTF-A), 9 suggesting that it may potentially also affect SMC phenotype through such pathways. Interestingly, our findings demonstrate an unusual case of dissociation of several key hallmarks of SMC phenotypic modulation. Generally, differentiated SMCs are quiescent and nonmigratory, and express contractile proteins, whereas dedifferentiated cells are proliferative and migratory, and downregulate contractile proteins but upregulate ECM synthesis. We report that in the absence of LMO7, SMCs demonstrate increased proliferation and ECM, but also increased expression of the contractile protein ACTA2 (Figures 2A and 3E, Figures IIIC, VI , and VIIIA in the online-only Data Supplement). This is consistent with the known role of TGF-β in inducing SMC contractile protein expression, as well as the robust ACTA2 expression characteristic of myofibroblasts. How LMO7 A and B, Immunofluorescence of p-SMAD3 (green), ACTA2 (red), and LMO7 (white) and DAPI nuclear staining in tissue sections of biopsies from patients with (A) CAV (n=4) or normal control coronary arteries (n=2) or (B) patent normally remodeling vein from AVF (n=3) or normal control veins (n=3). Preliminary analysis of a small number of samples suggests that LMO7 expression level was elevated in the diseased arteries or veins. Quantification of staining in entire section is shown in the upper graph in each panel. White boxes in the CAV images indicate areas shown in high-power insets to the right of each CAV images to illustrate inverse correlation between p-SMAD3 and LMO7 in representative individual cells. Twenty to 32 cells in total from each of several sections from each patient sample were randomly selected for quantitation of the staining intensity of LMO7 and p-SMAD3, which are plotted in the lower graphs. In CAV samples, the average expression of LMO7 and p-SMAD3 from each patient sample was presented as a single data point in the correlation graphs to confirm the inverse correlation between LMO7 and p-SMAD3 in the diseased patient samples (each individual patient color coded in graphs for clarity). R 2 and P values for correlation curves are shown. Data are expressed as mean±SEM. ***P<0.001, ****P<0.0001. DAPI indicates 4′,6-diamidino-2-phenylindole; and p-SMAD3, SMAD3 phosphorylation.
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may also modulate fibrotic response through additional pathways such as MRTFs 9,44 may be an interesting topic for future studies.
TGF-β is a key driver of intimal hyperplasia following vascular injury. 17 Whereas SMC proliferation is limited to the first 2 to 3 weeks postinjury, human lesions continue to grow as a result of ongoing ECM deposition, resulting in luminal scar formation that can limit flow and require revascularization. 2 We identify LMO7 as a factor that is induced by TGF-β and in turn limits TGF-β signaling, ECM deposition, and proliferation in murine neointimal lesions. Importantly, preliminary studies also support elevated LMO7 expression relative to control vein or artery in the human neointimal pathologies AVF and cardiac allograft vasculopathy, in which TGF-β is also associated with exacerbated neointima formation. 37, 38 In our control mouse and human specimens, LMO7 levels are very low in normal, mature blood vessels. Our data suggest that the increase in LMO7 that occurs in the context of active vascular remodeling serves to restrain the progression of intimal hyperplasia, as the complete absence of LMO7 in our mouse models results in very severe neointimal formation. The cardiac allograft vasculopathy hyperplastic vessels reveal an inverse correlation between LMO7 and p-SMAD3 expression, consistent with our mouse vascular injury findings. There was a similar trend in the relationship between LMO7 and p-SMAD3 expression in the AVF samples, but the small sample size precludes definitive conclusions. Future studies with larger numbers of patients would allow us to elucidate the relationship between LMO7 expression and disease severity in human lesions.
TGF-β contributes to other vascular pathologies as well. In atherosclerosis, TGF-β exerts a protective role by inducing SMC ECM deposition and suppressing leukocyte inflammation and endothelial adhesion molecule expression. 45 TGF-β signaling exerts protective effects in thoracic aortic aneurysm development. 46 It will therefore be of interest to evaluate LMO7 function in these diseases. Moreover, feedback regulation of TGF-β signaling may also explain the previous observation of spontaneous lung carcinoma in aged Lmo7 −/− mice, 11 given the known function of TGF-β in tumor metastasis. 47 LMO7 has a broad tissue distribution, with high expression in tissues prone to fibrosis. 11 Even though distinct cell types contribute to fibrosis in different organs (fibroblasts, hepatic stellate cells, and SMCs), these cells share the characteristic of transdifferentiation into myofibroblast-like cells, 48 the main source of ECM. As progressive fibrosis leads to loss of normal organ function, often with transplantation as the only solution for the end-stage fibrotic diseases, 49 further elucidating the role of LMO7 in wound healing resolution may have clinical benefit to alleviate adverse fibrogenesis.
